{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "KALV",
  "name": "KalVista Pharmaceuticals, Inc.",
  "url": "https://orbyd.app/dossiers/KALV/",
  "json_url": "https://orbyd.app/dossiers/KALV.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Closed takeout, not a security: Chiesi's $27.00/share all-cash acquisition of KalVista completed 2026-06-11, shares delisted from Nasdaq with deregistration (POS AM, Form 25, Form 15) underway. No spread, no momentum leg, no listed share to trade — retained only so a stale screen doesn't re-flag a delisted ticker as a fresh breakout.",
  "invalidation_trigger": "A daily close below $27.00 can no longer print — KALV was delisted from Nasdaq before the open on 2026-06-11 at the $27.00 cash consideration, the merger is closed, and no US-listed equity remains; deregistration is underway. Only a formal deal reversal and relisting (no precedent) reopens it.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "rare-disease-gene-therapy",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-04-29: Chiesi Group definitive agreement to acquire KALV at $27.00/share cash, ~$1.9B, 36% premium to 30d VWAP.",
    "2026-04-29: Chiesi Group definitive agreement to acquire KALV at $27.00/share cash, ~$1.9B, 36% premium to 30d VWAP. Tender via Skyline Merger Sub commenced 2026-05-13.",
    "If the engine ever re-surfaces KALV on a stale '52-wk-high / above all MAs' breakout trigger, it is a dead ticker pin from pre-delisting data — ignore.",
    "RESOLVED/UNTRADEABLE: Chiesi-KalVista merger completed 2026-06-11 at $27.00/share cash; KALV delisted from Nasdaq before the open same day; company now a wholly owned Chiesi subsidiary.",
    "Deregistration underway: Nasdaq Form 25 filed, POS AM filed to deregister S-3 shelf securities, Form 15 (Exchange Act) pending; insider Form 4s show options closed out at $27.00. No relisting path absent a deal reversal (no precedent).",
    "all regulators cleared pre-close (US HSR 2026-05-28, Germany GWB 2026-05-27, Italy FDI 2026-05-29).",
    "3.250% Convertible Senior Notes due 2031 settled at $1,606.28 cash per $1,000 principal, at parity with the $27.00 equity consideration.",
    "EKTERLY (sebetralstat) fundamentals (kept for reference, now private): ~$49M FY2025 net rev (~$35M Q4 2025), ~20% US HAE penetration, 724 prescribers / 1,702 patient start forms thru 2026-02-28; Japan/Germany/UK launches 2026.",
    "STALE-DATA HAZARD: frozen $27.00 tape will trip 'price at 52-wk high / above all MAs' breakout rules with zero tradability. Exclude from momentum/breakout scans; any signal is a stale-price false positive.",
    "Standalone deal-break reversion (moot) was ~$15-16; 52-wk low $9.83. Never a momentum name — sub-2% capped spread vs ~40% binary downside throughout."
  ],
  "body_markdown": "## Current Thesis\nKALV is a resolved takeout, not a live security. Chiesi Farmaceutici S.p.A.'s $27.00/share all-cash acquisition closed on **2026-06-11**, with KalVista continuing as a wholly owned Chiesi subsidiary. The second-step merger converted the remaining stock into the same $27.00 cash. Shares **ceased trading on the Nasdaq Global Market before the open on 2026-06-11**, and the wind-down has since advanced — a POS AM has been filed to deregister the shelf securities, Form 4 filings show directors and officers cashing out options at the $27.00 price, and Form 15 deregistration under the Exchange Act follows Nasdaq's Form 25. There is no spread, no momentum leg, and no listed share — this file stays open only so a stale price feed doesn't resurface a delisted ticker as a fresh breakout.\n\n## Bull Case\n- **The deal completed clean and ahead of the original timeline.** Announced 2026-04-29 at a 36% premium to the 30-day VWAP (~$1.9B), the transaction cleared every regulator early — US HSR waiting period expired 2026-05-28, Germany's FCO declined to meet GWB prohibition criteria 2026-05-27, Italy's FDI authority confirmed no objection 2026-05-29 — then closed 2026-06-11, faster than the initial Q3-2026 placeholder. Tendering holders received $27.00 cash;\n- **The underlying asset was real, which is why the arb never wobbled.** EKTERLY (sebetralstat), the first oral on-demand therapy for hereditary angioedema, booked roughly **$49M FY2025 net revenue (~$35M in Q4 2025 alone)** with **1,702 patient start forms, ~20% US HAE penetration, and 724 prescribers through 2026-02-28**, plus Japan (Kaken), Germany and UK launches underway in 2026. That revenue floor kept deal-break odds negligible into the close.\n- **The convertible tail settled at parity.** Holders of the 3.250% Convertible Senior Notes due 2031 received the right to convert each $1,000 note into **$1,606.28 cash**, aligning the credit with the $27.00 equity consideration — a clean settlement, not a residual claim.\n\n## Bear Case\n- **There is nothing to trade.** The equity is delisted and mid-deregistration (POS AM filed, Form 25 lodged, Form 15 pending). Any momentum, breakout, or mean-reversion read is now arithmetic on a frozen tape.\n- **The franchise is private.** Listed exposure to EKTERLY and the HAE rare-disease theme through this name is gone; it sits inside Chiesi's privately held portfolio, unreachable via a public share.\n- **The whole arc was a cap-and-crash payoff, never a trend.** From the 2026-04-29 announcement gap into the close, the stock offered a sub-2% capped spread to $27.00 against roughly 40% deal-break reversion toward $15–16 (52-week low $9.83) — pennies of upside in front of binary downside, with zero trend velocity for a momentum book to work with.\n- **Stale-data risk is the only remaining hazard.** A screen keyed to pre-delisting prices will keep flagging KALV near its 52-week high and above every moving average — a phantom breakout with no liquidity behind it.\n\n## Setup & Price Structure\n- **Terminal print:** $27.00 cash. The last Nasdaq tape stopped before the 2026-06-11 open; there is no live quote, no bid/ask, and no float to accumulate. Shares outstanding were 53,240,888 as of 2026-05-06; ~43.15M tendered.\n- **Moving-average / RSI reads are meaningless.** Any indicator will compute off the frozen $27.00 level and report the name \"above all MAs / near 52-week high.\" Treat every such signal as a data artifact, not a setup — this ticker will trip breakout rules with no tradability behind them.\n- **No reversion path.** A completed short-form merger plus deregistration does not unwind; there is no scenario in which the stock relists and re-prices absent a deal reversal, which has no precedent here.\n\n## Catalyst Calendar (next 30 days)\n\n- **No earnings, no FDA/PDUFA, no analyst catalysts.** H.C. Wainwright had already cut to Neutral on the merger (de-rating, no standalone story); coverage is winding down. There is no dated catalyst that produces a tradeable move, because there is no listed share.\n\n## Elapsed catalysts\n\n- **Form 15 deregistration effectiveness (~2026-07/08, est.):** completes suspension of Exchange Act reporting following the 2026-06-11 Form 25 delisting. Administrative only — no tradeable event. *(passed 59d ago)*\n\n## What Would Change Our Mind\nThe read reopens only on a genuine relisting event: a definitive merger termination or reversal that returns KALV to a US exchange with a live quote, restored SEC reporting, and real float. A daily close below $27.00 can no longer print — the stock is delisted at the $27.00 cash consideration and the merger is closed. Short of a formal deal unwind (no precedent in this situation), nothing about EKTERLY's launch trajectory, HAE competitive dynamics, or Chiesi's private strategy is expressible through a tradeable KALV share, so none of it changes the stance: there is no security here.\n\n## Correlation Notes\n- **Special-situation, not thematic, exposure while it lived.** During the deal window KALV traded off deal-completion odds, not the biotech tape (XBI) or rates — its correlation to sector beta was near zero by design. Post-close it correlates with nothing; it is a settled cash event.\n- **HAE / rare-disease read-through goes elsewhere.** Investors wanting listed exposure to the oral-HAE thesis EKTERLY validated must look to peers still on-exchange (e.g. the broader plasma-kallikrein and C1-inhibitor complex); KALV no longer carries that beta.\n- **Watchlist hygiene:** flag as delisted/closed so the name is excluded from breakout and momentum scans; any signal it generates is a stale-price false positive.",
  "first_seen": "2026-05-17",
  "last_analyzed": "2026-07-18T07:55:11+00:00",
  "last_synthesized": "2026-07-18",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}